secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-04-10T23:59:59+00:00
Accession:  0001658247-26-000022
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics COO Jeff Knight resigns, enters consulting agreement at $400/hr
-------------------------------------------------------------------------

- Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026 (previously reported March 23, 2026).
- 1-year consulting agreement with $400/hour rate, max 20 hours/month, renewable for 6 months.
- Unvested restricted stock units and options forfeited; vested options exercisable three months after consulting ends.
- Consulting agreement includes a general release of all claims against the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000022/0001658247-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000022/crnx-20260410.htm
  HTML page:      https://secwatch.observer/filing/0001658247-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer